Study design For this randomized, open-label, single-centre, phase 2 trial, patients were enrolled at the ...
While sparsentan blocks both ETA and AT1 receptors, atrasentan (Vanrafia) is a targeted therapy that ...
Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of ...